Needham Rates Starling Oncology (TOI) buy, $7 Price Target
Needham maintains its buy rating on TOI, setting a price target of $7, a 31.21% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Needham rated Starling Oncology Inc ($TOI) "buy" with a $7 price target on June 17, 2026.
Since the rating, $TOI is down 0.6% after 1 week and down 0.6% to date (from the $5.25 close on Jun 17, 2026).
TOI
Starling Oncology Inc
Key Points
- Needham reiterated its buy rating on TOI with a price target of $7, as of June 17, 2026.
- Needham's $7 price target implies 31.21% upside from Starling Oncology Inc's ($TOI) current $5.33 share price.
- TOI shares are trading at $5.27, with notable insider buying and selling activity recently.
- Institutional investors like BlackRock and Vanguard have adjusted their positions in TOI.
Get $TOI trade alerts by text
We text you when insiders, Congress or big funds trade $TOI. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Starling Oncology Inc alert may contain errors. Disclosures
On June 17, 2026, Needham reiterated its buy rating for TOI, setting a price target of $7. The analyst, Matthew Shea, continues to see potential upside for the stock, which is currently trading at $5.27.
Other Institutional Activity in TOI
BlackRock, Inc. increased its holdings in TOI by 510,534 shares, bringing its total to 4,415,867 shares valued at about $13.6 million. Vanguard Capital Management LLC also made a significant move, adding 3,476,781 shares, resulting in a total of 3,476,781 shares worth approximately $10.7 million. Deerfield Management Company, L.P. maintained its position with 3,360,052 shares valued at $10.3 million. Kanen Wealth Management LLC reduced its stake by 198,286 shares, ending with 2,777,858 shares valued at $8.5 million. Meanwhile, Balyasny Asset Management L.P. cut its holdings by 692,067 shares, leaving it with 1,826,370 shares worth $5.6 million.
TOI Stock Snapshot
TOI shares are trading at $5.27. The stock has seen various institutional movements, reflecting differing strategies and outlooks. Investors are keeping an eye on these changes as they assess TOI's future performance.
$TOI price target
Starling Oncology Inc daily closes and this analyst's $7 target. Not advice.
Insider Buying and Selling at Starling Oncology Inc
Recent insider activity at TOI includes several transactions. On June 8, 2026, Chief Medical Officer Yale Podnos sold 23,451 shares at an average price of $5.38 under a planned sale. Earlier, on June 4, 2026, an individual named Jorey Chernett purchased 12,000 shares at $4.75. On May 21, 2026, Chief Financial Officer Robert Ross and CEO Daniel Virnich each sold shares at $4.47, with Ross selling 1,604 shares and Virnich selling 23,058 shares.
Analysts Set New Price Targets
On June 17, 2026, Needham maintained its buy rating on TOI with a price target of $7. BTIG also maintained its buy rating with an $8 target on June 8, 2026. B. Riley Securities maintained a buy rating with an $8 target back on March 13, 2026. The consensus among analysts is bullish, with a strong buy recommendation and a mean target price of $7.33.
Bottom Line
Needham's reiterated buy rating and $7 price target reflect continued optimism about TOI's prospects. The stock's current trading price of $5.27 suggests potential upside. Institutional and insider activities provide additional context for investors evaluating their positions. As always, these analyst ratings are based on past data and should be considered with other factors in mind.
Related Filing Alerts
Source: Needham's rating change on $TOI (Jun 17, 2026). Written by software, not financial advice. How we make alerts